Enrich Therapeutics selected to be part of the 2022 MassChallenge US early-stage accelerator program!

Branford, CT July 11th, 2022 / MassChallenge has officially named the 2022 cohort for the US early-stage program, and Enrich Therapeutics Inc. is pleased to be one of them! We look forward to all we will gain throughout this program, and we’re excited to tap into the @MassChallenge global network of world-class mentors and partners.

MassChallenge is the global network for innovators. It supports entrepreneurs and startups through the early stages of building a business. Founded in 2009, MassChallenge’s  mission is to equip bold entrepreneurs to disrupt the status quo and create sustainable change.     
 
Through MassChallenge’s global network, entrepreneurs get access to industry-based mentors and resources to support every area of the startup lifecycle so they can help solve some of the world’s most massive challenges. MassChallenge’s hyper-focused, proven methodology helps founders identify goals and key initiatives, providing access to a meaningful network of experts and mentors, while also providing connection to a deep peer network from across the global community.

About Enrich Therapeutics Inc.:
Enrich Therapeutics Inc., headquartered in Branford, CT, is dedicated to accelerating our cell discovery innovation to benefit global biomedical researchers.

Enrich’s groundbreaking cell technology enables a streamlined workflow of cell co-culturing, kinetics profiling, and guided capturing based on cell functions. Our unique features are microfluidics-free, dissolvable microwell, and visual enrichment. They eliminate those insuperable pain points of existing technology. We discover meaningful clone, not by predicting cell function, but by observing cell function.

Enrich team assembled with experienced startup operators, scientific innovators, and life science researchers, also backed by a great set of seasoned investors and advisors. We partner with world-class research institutions to develop critical applications on our platform technology, such as therapeutic T cell discovery and patient tumor cell line generation.

Additional information about the company may be found at www.enrichtx.com.

For more information:

Investor Contact:
investors@enrichtx.com

General Contact:
inquiry@enrichtx.com